Agreement initiates development of therapy for neurodegenerative diseases

Georg-August-University Göttingen (UMG) and UK medical research charity MRC Technology (MRCT), have signed an agreement for the development of a novel therapy for neurodegenerative diseases based on antibody targeting amyloid beta peptides 4-x. The aim is to develop a therapy for Alzheimer's Disease (AD).

The license, negotiated by MBM ScienceBridge GmbH, the technology transfer organisation of the Georg-August-Universität Göttingen, will enable UMG to access the antibody humanisation expertise of MRCT’s Centre for Therapeutics Discovery and the work of its Therapeutic Antibody Group, led by Dr. David Matthews.

MRCT will receives an exclusive worldwide license to the IP rights of UMG related to a novel therapeutic approach for the treatment of sporadic and familial AD, based on a panel of unique antibodies developed by its scientist Prof. Dr. Thomas Bayer. MRCT and UMG will then receive downstream payments dependent on the successful development and out-licensing of the antibody. This income will be used for further research within the organisations.